| |
FEC100-taxotere
|
FEC100-taxotere-herceptin
|
|---|
|
N = 118
|
%a
|
N = 46
|
%a
|
|---|
|
Tumor type
|
|
Ductal carcinoma
|
106
|
89.9
|
44
|
95.6
|
|
Lobular carcinoma
|
7
|
5.9
|
1
|
2.2
|
|
Other
|
5
|
4.2
|
1
|
2.2
|
|
Tumor size
|
|
T0-T1
|
5
|
4.3
|
1
|
2.3
|
|
T2
|
60
|
51.7
|
21
|
48.8
|
|
T3
|
24
|
20.7
|
11
|
25.6
|
|
T4
|
27
|
23.3
|
10
|
23.3
|
|
NA
|
2
|
1.7
|
3
|
6.5
|
|
Histoprognostic grade
|
|
SBRI
|
7
|
6.7
|
1
|
2.5
|
|
SBRII
|
54
|
51.9
|
19
|
47.5
|
|
SBRIII
|
43
|
41.3
|
20
|
50
|
|
NA
|
14
|
11.9
|
6
|
13.1
|
|
Nodal status
|
|
Positive
|
63
|
54.3
|
30
|
65.2
|
|
Negative
|
53
|
45.7
|
16
|
34.8
|
|
NA
|
2
|
1.7
|
0
|
0
|
|
Hormone receptor status
|
|
Positiveb
|
77
|
66.3
|
23
|
50.0
|
|
Negativec
|
39
|
33.6
|
23
|
50.0
|
|
NA
|
2
|
1.7
|
0
|
0.0
|
|
HER-2 status
|
|
Positived
|
5
|
4.7
|
46
|
100.0
|
|
Negative
|
102
|
95.3
|
0
|
0.0
|
|
NA
|
11
|
9.3
|
0
|
0.0
|
|
Clinical response
|
|
CR
|
11
|
12.2
|
7
|
21.9
|
|
PR
|
62
|
68.9
|
23
|
71.9
|
|
SD
|
15
|
16.7
|
2
|
6.3
|
|
PD
|
2
|
2.2
|
0
|
0.0
|
|
NA
|
28
|
23.7
|
14
|
30.4
|
|
pCR
|
|
Yes
|
25
|
21.2
|
18
|
40.0
|
|
No
|
93
|
78.8
|
27
|
60.0
|
|
NA
|
0
|
0.0
|
1
|
2.2
|
-
CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not applicable, pCR pathological complete response.
-
aPercentages of evaluable patients (except for NA: percentage of all patients).
-
bEstrogen receptor or progesterone receptor positive.
-
cEstrogen receptor and progesterone receptor negative.
-
dIHC3+ or IHC2+/FISH+ or CISH+.
